Zetam Pharmaceuticals Obe bile acid magnesium tablets have been approved for clinical trials of the drug

The announcement shows that the magnesium obe bile acid tablets are the company's own research and development of 2.1 new drugs, is the European and American marketed drugs obecholic acid and crystal-modified modified new drugs.
orbigate is a Farniol X-subjector astigtor that regulates the metabolism of cholesterol lipoproteins and bile acid (BAs) and improves immune inflammation and fibrosis.
As a result, magnesium obechotic acid is expected to be developed as a treatment for primary bileitis (PBC), non-alcoholic fatty hepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), gallstones, primary sclerotic bileitis (PSC) and other drugs.
the original drug obecholic acid was approved by the FDA and the European Commission in June and December 2016 for the treatment of primary bileitis (PBC), according to Obe bile acid manufacturers According to publicly available data released by Intercept, Oberic acid sales in the U.S. and Europe were $249.6 million in 2019 and $229.4 million in the U.S. and Europe in the first three quarters of 2020.
so far, Obeid bile acid has not been listed in China.
source: Zee-Yu Bio-Announcement